Cell Culture

Continued from page 43

34 Heubsch, N, Loskill, P, Deveshwar, N et al. Miniaturized iPS-Cell-Derived Cardiac Muscles for Physiologically Relevant Drug Response Analyses. Sci. Rep. 2016, 6, 24726. 35 Nath, S, Devi, G. Three- Dimensional Culture Systems in Cancer Research: Focus on Tumor Spheroid Model. Pharmacol. Ther. 2016, 163, 94-108. 36 Bian, W, Badie, N, Herman, DH et al. Robust T-Tubulation and Maturation of Cardiomyocytes Using Tissue- Engineered Epicardial Mimetics. Biomaterials 2014, 35, 3819-3828. 37 Hirt, MN, Sorensen, NA, Bartholdt, LM et al. Increased Afterload Induces Pathologic Cardiac Hypertrophy: A New In Vitro Model. Basic Res. Cardiol. 2012, 107, 307-312. 38 Nunes, SS, Miklas, JW, Liu, J et al. Biowire: A Platform for Maturation of Human Pluripotent Stem Cell-Derived Cardiomyocytes. Nat. Methods 2013, 10, 781-787. 39 Mathur, A, Loskil, P, Shoa, K et al. Human iPSC-Based Cardiac Microphysiological System for Drug Screening Applications. Sci. Rep. 2015, 5, 8883. 40Tiburcy, M, Didier, M, Boy, O et al. Terminal Differentiation, Advanced Organotypic Maturation, and Modeling of Hypertrophic Growth in Engineered Heart Tissue. Circ. Res. 2011, 109, 1105-1114. 41Workman, MJ, Mahe, MM, Trisno, S et al. Engineered Human Pluripotent-Stem-Cell- Derived Intestinal Tissues with a Functional Enteric Nervous System. Nat. Med. 2017, 23, 49-59. 42 Zhang, RR, Koido, M, Tadokoro, T et al. Human iPSC Derived Posterior Gut Progenitors Are Expandable and Capable of Forming Gut and Liver Organoids. Stem Cell Rep. 2018, 10, 780-793.

drugs. Compared to 2D cell culture, 3D cultures provide more architecturally-relevant barriers for compounds to pass through, a critical factor in determining efficacy. Additionally, 3D culture sys- tems better model cell-cell interaction, a benefit most apparent in complex tissues such as the brain. Finally, the temporal aspect of 3D cell culture – which in many cases is long lived – is important when modelling diseases such as neurodegenera- tive diseases, which are often slow to develop. As researchers have become more proficient

with 3D techniques, the models being created have become more complex. Researchers can better study the in vivo functionality of tissue and organ systems, and monitor patient-specific response to treatment. The generation of organ-specific organoids using hPSCs are proving to be particu- larly powerful tools for cancer research as they allow for the study of organ development and tis- sue morphogenesis, as well as better modelling of diseases24. These advances, along with those in high throughput screening, are leading to more clinically-relevant models. In the future, researchers will likely continue to

move more toward patient-specific treatments and personalised medicine. Technologies and methods such as those used to generate patient-specific organoids, renewable human tissue24 and 3D bio- printed cancer models25 are advancing and provid- ing a window into the future.

Acknowledgement Thank you to Dr Wesley (Lien-Yu) Hung of the Corning Research Center Taiwan for his neural stem cell spheroid data.


Dr Amanda Linkous previously served as the Director of the Starr Foundation Cerebral Organoid Translational Core at Weill Cornell Medicine (New York, NY). Dr Linkous is currently the Scientific Center Manager for the NCI’s Center for Systems Biology of Small Cell Lung Cancer (SCLC) at Vanderbilt University, where she is developing similar 3D model systems to study the biology and refractory nature of SCLC (Nashville, TN). She completed her postdoctoral training in the Neuro-Oncology Branch at the National Cancer Institute (Bethesda, MD).

Hilary Sherman is a Senior Scientist in the Corning Life Sciences Applications Lab located in Kennebunk, ME. Hilary has been with Corning Incorporated since 2005 and has worked with a wide variety of cell types including mammalian,

44 Drug Discovery World Spring 2019

insect, primary and stem cells in a vast array of applications. Her key roles at Corning involve cre- ating technical documents such as protocols and whitepapers as well as providing technical support and training for both the Corning sales force and customers. Hilary received her BS degree in Biology from the University of New Hampshire.

Mei (Iris) Li is Director, Global Scientific Applications and Support of Corning Life Sciences. Iris has been with Corning Life Sciences since 2008. She focuses on management of field applica- tions support, technical call centres and technology centres. She has experience in developing a strong support base for product applications and ensuring the successful implementation of technology strat- egy in defined markets. Iris holds a Masters degree in Biology from the College of William and Mary.

Dr Richard M. Eglen is currently Vice-President and General Manager of Corning Life Sciences, an operating division of Corning Incorporated based outside of Boston, Massachusetts (USA). Dr Eglen has more than 40 years’ experience in the Life Sciences industry. Prior to joining Corning in 2011, he was President of bio-discovery at PerkinElmer and held other executive management positions in the pharmaceutical, diagnostic and biotech industries. Dr Eglen has extensive experi- ence in drug discovery, including serving as Executive Vice-President for research and develop- ment at DiscoveRx Corp (now Eurofins Pharma Discovery Services), and as Vice-President of the Center for Biological Research at Roche Pharmaceuticals. At Roche, he was responsible for leading drug discovery programmes in the areas of cardiovascular disease, migraine, neuropathic pain and urinary tract disorders.

Page 1  |  Page 2  |  Page 3  |  Page 4  |  Page 5  |  Page 6  |  Page 7  |  Page 8  |  Page 9  |  Page 10  |  Page 11  |  Page 12  |  Page 13  |  Page 14  |  Page 15  |  Page 16  |  Page 17  |  Page 18  |  Page 19  |  Page 20  |  Page 21  |  Page 22  |  Page 23  |  Page 24  |  Page 25  |  Page 26  |  Page 27  |  Page 28  |  Page 29  |  Page 30  |  Page 31  |  Page 32  |  Page 33  |  Page 34  |  Page 35  |  Page 36  |  Page 37  |  Page 38  |  Page 39  |  Page 40  |  Page 41  |  Page 42  |  Page 43  |  Page 44  |  Page 45  |  Page 46  |  Page 47  |  Page 48  |  Page 49  |  Page 50  |  Page 51  |  Page 52  |  Page 53  |  Page 54  |  Page 55  |  Page 56  |  Page 57  |  Page 58  |  Page 59  |  Page 60  |  Page 61  |  Page 62  |  Page 63  |  Page 64